UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

Withdrawn before enrolling · Phase 1

Conditions studied: Multiple Myeloma

In brief

The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.

Key facts

Study ID

NCT00578045

Run by

University of Arkansas

People needed

0

Starts

2006-07-01

Expected to finish

2011-03-01

Last updated by the study team

2015-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced hematological malignancies who have failed at least two lines of therapy.
• Karnofsky performance score > 60, unless due to disease and then > 50.
• Age > 18 years.
• An expected survival of > 3 months.
• Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study.
• Cord blood must have negative serology for HIV.
• Release of cord blood.
• The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight.

You may not qualify if…

• Liver function: total bilirubin > 2x ULN or AST/ALT > 3x ULN.
• Creatinine > 3.0 mg/dL.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.